Literature DB >> 8712697

Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT.

P Bader1, W Hölle, T Klingebiel, R Handgretinger, D Niethammer, J Beck.   

Abstract

Patients who develop mixed hematopoietic chimerism (MHC) after allogeneic bone marrow transplantation (allo-BMT) might have an increased risk of relapse or graft failure. In order to identify patients with MHC we established a quantitative polymerase chain reaction (PCR) approach to estimate the individual degree of autologous recovery and investigate the dynamics of MHC posttransplant. Therefore standardized mixed chimeric samples were generated in each individual case by mixing pretransplant recipient and donor DNA at a range of percentages. After amplification the samples were analyzed densitometrically and signal intensities were taken as the basis of individual standard curves. Subsequently posttransplant DNA samples were also analyzed, the intensity of the informative signals were compared to the standard curves and autologous recovery was expressed in percentage related to host DNA. We investigated 40 pediatric patients receiving allo-BMT by this method. 10/40 developed MHC during course of the observation period. Each patient with MHC revealed a certain dynamic. This approach might be helpful when deciding on early intervention and additional treatment to prevent graft failure or relapse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712697

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Concordance of genotypes in pre- and post-lung transplantation DNA samples.

Authors:  Dawn L DeMeo; John J Reilly; Leo C Ginns; Jody S Sylvia; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-30       Impact factor: 6.914

2.  Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.

Authors:  Caroline Woehlecke; Susan Wittig; Juliane Sanft; Hermann Kreyenberg; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-24       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.